



02-05-03

#17/c  
gnd  
3/11/03 1632/\$  
CASE 4-30683A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV195227212US  
Express Mail Label Number

FEBRUARY 4, 2003  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
FEB 10 2003  
TECH CENTER 1600/2900

IN RE APPLICATION OF

Art Unit: 1632

AMLOT ET AL.

Examiner: Gerald Ewoldt

APPLICATION NO: 09/770,002

FILED: JANUARY 25, 2001

FOR: USE OF CD25 BINDING MOLECULES IN THE TREATMENT OF  
RHEUMATOID ARTHRITIS OR SKIN DISEASES

Assistant Commissioner for Patents  
Washington, D.C. 20231

AMENDMENT

Sir:

This is in response to the Office Action dated September 5, 2002 having a shortened three (3) month period for response which expired on December 5, 2002. Applicants enclose herewith a petition for a two (2) month extension of time together with authorization to deduct the appropriate fee. Please amend the above-identified application as follows.

IN THE CLAIMS:

✓  
Please cancel claims 1-3, 6 and 9-11 without prejudice.

Please amend claims 4 and 5 as follows:

C1  
4. (amended) A method for the treatment of rheumatoid arthritis in a patient in need of such treatment comprising administering to the patient an effective amount of a CD25 binding molecule; wherein the CD25 binding molecule comprises at least one antigen binding site comprising at least one domain which comprises in sequence, the hypervariable regions CDR1, CDR2 and CDR3; the CDR1 having the amino acid sequence Arg-Tyr-Trp-Met-His (SEQ ID NO: 1), the CDR2 having the amino acid sequence Ala-Ile-Tyr-Pro-Gly-Asn-Ser-Asp-Thr-Ser-Tyr-Asn-Gln-Lys-Phe-Glu-Gly (SEQ ID NO: 2), and the CDR3 having the amino acid sequence Asp-Tyr-Gly-Tyr-Tyr-Phe-Asp-Phe (SEQ ID NO: 3).